indazoles has been researched along with Carcinoma, Pancreatic Ductal in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhutkar, A; Chen, PY; Chung, KM; Dorans, KJ; Hong, E; Jacks, T; Muzumdar, MD; Noll, EM; Sprick, MR; Trumpp, A | 1 |
| Cheng, L; Li, X; Yang, F; Zhang, L | 1 |
| Abe, T; Ando, Y; Fei, S; Feng, H; Guan, W; Hashizume, M; Iwamoto, C; Kibe, S; Koikawa, K; Miyasaka, Y; Mizumoto, K; Moriyama, T; Nakamura, M; Nakata, K; Ohtsuka, T; Ohuchida, K; Shindo, K; Yan, Z; Zheng, B | 1 |
| Alessi, DR; Arbeiter, A; Baccarini, M; Dobler, M; Eser, S; Esposito, I; Gottschalk, K; Hieber, M; Kind, AJ; Klein, S; Kong, B; Messer, M; Michalski, CW; Rad, L; Rad, R; Reiff, N; Saur, D; Schlitter, AM; Schmid, RM; Schneider, G; Schnieke, AE; Seidler, B | 1 |
| Pattison, S; Zalcberg, JR | 1 |
| Bou-Reslan, H; Cao, T; Carano, R; Castillo, J; Chan, E; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, W; French, D; Hoeflich, KP; Junttila, MR; Merchant, M; Metcalfe, C; Nannini, MA; Otter, DD; Singh, M | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
1 review(s) available for indazoles and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
6 other study(ies) available for indazoles and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Survival of pancreatic cancer cells lacking KRAS function.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; DNA Copy Number Variations; Humans; Immunoblotting; Indazoles; Mice; Morpholines; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Purines; Pyrimidines; Pyrimidinones; Quinazolinones; Sulfonamides; Thiazoles | 2017 |
LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Survival; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Indazoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Piperazines; RNA, Long Noncoding | 2018 |
Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis.
Topics: Animals; Autophagy; Carcinoma, Pancreatic Ductal; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chloroquine; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Indazoles; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Metastasis; Pancreatic Neoplasms; Pancreatic Stellate Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Stromal Cells; Xenograft Model Antitumor Assays | 2019 |
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Activation; Humans; Indazoles; Lithostathine; Metaplasia; Mice; Mice, Inbred NOD; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Signal Transduction; Sulfonamides; TNF Receptor-Associated Factor 3; Transplantation, Heterologous; Tumor Cells, Cultured | 2013 |
Bespoke treatment: drivers beware!
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fatal Outcome; Female; Humans; Indazoles; Liver Neoplasms; Microtubule-Associated Proteins; Middle Aged; Molecular Targeted Therapy; Mutation; Oncogenes; Pancreatic Neoplasms; Paraneoplastic Syndromes; Pyrimidines; Radiography; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides | 2014 |
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Indazoles; MAP Kinase Kinase 1; Mice; Models, Biological; Mutation; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Standard of Care; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |